Reduced expression of AMPK-β1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Li, Cuilan ^a,c   Liu, Vincent W S ^a   Chiu, Pui M ^a   Yao, Kwok Ming ^b   Ngan, Hextan Y S ^a   Chan, David W ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

AKT; AMPK activation; AMPK 1; ERK; JNK; Ovarian cancer

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE BETA1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENICITY; CELL CYCLE ARREST; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLONOGENIC ASSAY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; OVARY CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WOUND HEALING;

AMP-ACTIVATED PROTEIN KINASES; BLOTTING, WESTERN; CELL LINE, TUMOR; DISEASE PROGRESSION; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, CONFOCAL; OVARIAN NEOPLASMS; TISSUE ARRAY ANALYSIS; TRANSFECTION;

EID: 84899624803     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-49     Document Type: Article

References (57)

1. Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, Guan Y, Oeh J, Modrusan Z, Bais C, Sampath D, Ferrara N. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J 2012, 31:3513-3523. 10.1038/emboj.2012.183, 3433782, 22773185.
2. Gomez Garcia I, Kortazar D, Oyenarte I, Mato JM, Martinez-Chantar ML, Martinez-Cruz LA. Purification, crystallization and preliminary crystallographic analysis of protein MJ1225 from Methanocaldococcus jannaschii, a putative archaeal homologue of gamma-AMPK. Acta Crystallogr Sect F: Struct Biol Cryst Commun 2009, 65:813-817. 10.1107/S1744309109026475, 2720341, 19652347.
3. Liu YN, Yin JJ, Abou-Kheir W, Hynes PG, Casey OM, Fang L, Yi M, Stephens RM, Seng V, Sheppard-Tillman H, Martin P, Kelly K. MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene 2013, 32:296-306. 10.1038/onc.2012.58, 22370643.
4. Wang Y, Chen Y, Gao L, Zhu MH. Expression and significance of neurogenic differentiation protein in pancreatic carcinoma. Zhonghua Bing Li Xue Za Zhi 2012, 41:23-27.
5. Wang D, Ye F, Sun Y, Li W, Liu H, Jiang J, Zhang Y, Liu C, Tong W, Gao L, Sun Y, Zhang W, Seetoe T, Lee P, Suo J, Zhang DY. Protein signatures for classification and prognosis of gastric cancer a signaling pathway-based approach. Am J Pathol 2011, 179:1657-1666. 10.1016/j.ajpath.2011.06.010, 3181400, 21854745.
6. Syed Sameer A, Shah ZA, Abdullah S, Chowdri NA, Siddiqi MA. Analysis of molecular aberrations of Wnt pathway gladiators in colorectal cancer in the Kashmiri population. Hum Genomics 2011, 5:441-452. 10.1186/1479-7364-5-5-441, 3525962, 21807601.
7. Chang C, Lee SO, Yeh S, Chang TM. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene 2013, doi: 10.1038/onc.2013.274. [Epub ahead of print].
8. Spano D, Heck C, De Antonellis P, Christofori G, Zollo M. Molecular networks that regulate cancer metastasis. Semin Cancer Biol 2012, 22:234-249. 10.1016/j.semcancer.2012.03.006, 22484561.
9. Nguyen HT, Merlin D. Homeostatic and innate immune responses: role of the transmembrane glycoprotein CD98. Cell Mol Life Sci 2012, 69:3015-3026. 10.1007/s00018-012-0963-z, 22460579.
10. Nievergall E, Lackmann M, Janes PW. Eph-dependent cell-cell adhesion and segregation in development and cancer. Cell Mol Life Sci 1813-1842, 2012:69.
11. Wu J, Xie N, Zhao X, Nice EC, Huang C. Dissection of aberrant GPCR signaling in tumorigenesis-a systems biology approach. Cancer Genomics Proteomics 2012, 9:37-50.
12. He M, Wei MJ. Reversing multidrug resistance by tyrosine kinase inhibitors. Chin J Cancer 2012, 31:126-133. 10.5732/cjc.011.10315, 3777484, 22237041.
13. Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012, 485:661-665. 10.1038/nature11066, 3607316, 22660331.
14. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012, 13:251-262. 10.1038/nrm3311, 22436748.
15. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 2011, 13:1016-1023. 10.1038/ncb2329, 3249400, 21892142.
16. Das SK, Bhutia SK, Kegelman TP, Peachy L, Oyesanya RA, Dasgupta S, Sokhi UK, Azab B, Dash R, Quinn BA, Kim K, Barral PM, Su ZZ, Boukerche H, Sarkar D, Fisher PB. MDA-9/syntenin: a positive gatekeeper of melanoma metastasis. Front Biosci (Landmark Ed) 2012, 17:1-15. 10.2741/3911, 22201728.
17. Achyut BR, Yang L. Transforming growth factor-beta in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology 2011, 141:1167-1178. 10.1053/j.gastro.2011.07.048, 21839702.
18. Hodgson MC, Bowden WA, Agoulnik IU. Androgen receptor footprint on the way to prostate cancer progression. World J Urol 2012, 30:279-285. 10.1007/s00345-011-0743-7, 3360873, 21927983.
19. Moore AE, Young LE, Dixon DA. MicroRNA and AU-rich element regulation of prostaglandin synthesis. Cancer Metastasis Rev 2011, 30:419-435. 10.1007/s10555-011-9300-5, 3447743, 22005950.
20. Tandon M, Vemula SV, Mittal SK. Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets 2011, 15:31-51. 10.1517/14728222.2011.538682, 3016619, 21142802.
21. Louderbough JM, Schroeder JA. Understanding the dual nature of CD44 in breast cancer progression. Mol Cancer Res 2011, 9:1573-1586. 10.1158/1541-7786.MCR-11-0156, 21970856.
22. Tian M, Neil JR, Schiemann WP. Transforming growth factor-beta and the hallmarks of cancer. Cell Signal 2011, 23:951-962. 10.1016/j.cellsig.2010.10.015, 3076078, 20940046.
23. Osada S, Yoshida K. Application of biological study for met expression to cancer therapy. Anticancer Agents Med Chem 2010, 10:58-63. 10.2174/1871520611009010058, 20015003.
24. Nasarre P, Potiron V, Drabkin H, Roche J. Guidance molecules in lung cancer. Cell Adh Migr 2010, 4:130-145. 10.4161/cam.4.1.10882, 2852570, 20139699.
25. Pani G, Giannoni E, Galeotti T, Chiarugi P. Redox-based escape mechanism from death: the cancer lesson. Antioxid Redox Signal 2009, 11:2791-2806. 10.1089/ars.2009.2739, 19686053.
26. Li C, Liu VW, Chiu PM, Chan DW, Ngan HY. Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications. BMC Cancer 2012, 12:357. 10.1186/1471-2407-12-357, 3518102, 22897928.
27. Royuela M, Rodriguez-Berriguete G, Fraile B, Paniagua R. TNF-alpha/IL-1/NF-kappaB transduction pathway in human cancer prostate. Histol Histopathol 2008, 23:1279-1290.
28. Lee DF, Hung MC. Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin Cancer Res 2008, 14:5656-5662. 10.1158/1078-0432.CCR-08-0123, 2613770, 18794072.
29. Steeg PS, Horak CE, Miller KD. Clinical-translational approaches to the Nm23-H1 metastasis suppressor. Clin Cancer Res 2008, 14:5006-5012. 10.1158/1078-0432.CCR-08-0238, 2730725, 18698018.
30. Chan DW, Yu SY, Chiu PM, Yao KM, Liu VW, Cheung AN, Ngan HY. Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis. J Pathol 2008, 215:245-252. 10.1002/path.2355, 18464245.
31. Gavert N, Ben-Shmuel A, Raveh S, Ben-Ze'ev A. L1-CAM in cancerous tissues. Expert Opin Biol Ther 2008, 8:1749-1757. 10.1517/14712598.8.11.1749, 18847309.
32. Wallerand H, Reiter RR, Ravaud A. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways. Curr Opin Urol 2008, 18:524-532. 10.1097/MOU.0b013e3283097889, 18670279.
33. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
34. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008, 22:1276-1312. 10.1101/gad.1653708, 2732412, 18483217.
35. Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther 2008, 118:18-35. 10.1016/j.pharmthera.2008.01.001, 18374420.
36. Ishii H, Saito T. Cancer metastasis as disrupted developmental phenotype. Curr Genomics 2008, 9:25-28. 10.2174/138920208783884919, 2674302, 19424481.
37. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008, 27:3889-3900. 10.1038/onc.2008.35, 18317452.
38. Giretti MS, Simoncini T. Rapid regulatory actions of sex steroids on cell movement through the actin cytoskeleton. Steroids 2008, 73:895-900. 10.1016/j.steroids.2008.01.011, 18308352.
39. Kuriyama S, Mayor R. Molecular analysis of neural crest migration. Philos Trans R Soc Lond B Biol Sci 2008, 363:1349-1362. 10.1098/rstb.2007.2252, 2610123, 18198151.
40. Cordes N, Park CC. beta1 integrin as a molecular therapeutic target. Int J Radiat Biol 2007, 83:753-760. 10.1080/09553000701639694, 18058364.
41. Lee JJ, Chu E. First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Clin Colorectal Cancer 2007, 6(Suppl 2):S42-46.
42. Leivonen SK, Kahari VM. Transforming growth factor-beta signaling in cancer invasion and metastasis. Int J Cancer 2007, 121:2119-2124. 10.1002/ijc.23113, 17849476.
43. Sharikadze VV, Gongadze NV. The modulatory role of phospholipids, phosphorylcholine ethers and alkylphosphocholines in signal transduction. Georgian Med News 2006, 130:91-97.
44. Reynolds AR, Kyprianou N. Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. Br J Pharmacol 2006, 147(Suppl 2):S144-152. 1751493, 16465179.
45. Wilting J, Hawighorst T, Hecht M, Christ B, Papoutsi M. Development of lymphatic vessels: tumour lymphangiogenesis and lymphatic invasion. Curr Med Chem 2005, 12:3043-3053. 10.2174/092986705774933407, 16375699.
46. Fisher PB. Is mda-7/IL-24 a " magic bullet" for cancer?. Cancer Res 2005, 65:10128-10138. 10.1158/0008-5472.CAN-05-3127, 16287994.
47. Rogers SJ, Box C, Harrington KJ, Nutting C, Rhys-Evans P, Eccles SA. The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck. Expert Opin Ther Targets 2005, 9:769-790. 10.1517/14728222.9.4.769, 16083342.
48. Fuchs SY. De-regulation of ubiquitin-dependent proteolysis and the pathogenesis of malignant melanoma. Cancer Metastasis Rev 2005, 24:329-338. 10.1007/s10555-005-1581-0, 15986141.
49. Lee CW, Wong LL, Tse EY, Liu HF, Leong VY, Lee JM, Hardie DG, Ng IO, Ching YP. AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells. Cancer Res 2012, 72:4394-4404. 10.1158/0008-5472.CAN-12-0429, 3433393, 22728651.
50. Howell GM, Grandis JR. Molecular mediators of metastasis in head and neck squamous cell carcinoma. Head Neck 2005, 27:710-717. 10.1002/hed.20222, 15952195.
51. Li Q, Xu W. Novel anticancer targets and drug discovery in post genomic age. Curr Med Chem Anticancer Agents 2005, 5:53-63. 10.2174/1568011053352631, 15720261.
52. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 2004, 9(Suppl 5):18-30.
53. Finley RS. Overview of targeted therapies for cancer. Am J Health Syst Pharm 2003, 60:S4-10.
54. Katoh M. WNT2 and human gastrointestinal cancer (review). Int J Mol Med 2003, 12:811-816.
55. Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003, 30:39-50.
56. Rosenberg L, Lipsett M. Biotherapeutic approaches to pancreatic cancer. Expert Opin Biol Ther 2003, 3:319-337. 10.1517/14712598.3.2.319, 12662145.
57. Berenson JR. Advances in the biology and treatment of myeloma bone disease. Semin Oncol 2002, 29:11-16.